• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Accenture plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    6/20/25 6:43:34 AM ET
    $ACN
    Business Services
    Consumer Discretionary
    Get the next $ACN alert in real time by email
    acn-20250620
    0001467373false00014673732025-06-202025-06-20

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of the
    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 20, 2025

    AccentureLogo.jpg
    Accenture plc
    (Exact name of Registrant as specified in its charter)
    Ireland001-3444898-0627530
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
    1 Grand Canal Square
    Grand Canal Harbour
    Dublin 2, Ireland
    (Address of principal executive offices)
    Registrant’s telephone number, including area code: (353) (1) 646-2000
    Not Applicable
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Class A ordinary shares, par value $0.0000225 per shareACNNew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 2.02 Results of Operations and Financial Condition
    On June 20, 2025, Accenture plc (“Accenture”) issued a news release announcing financial results for its third quarter of fiscal 2025, which ended on May 31, 2025.
    A copy of the news release is attached hereto as Exhibit 99. All information in the news release is furnished but not filed.
    Non-GAAP Financial Information
    In the attached news release Accenture discloses the following non-GAAP financial measures:
    •Free cash flow (defined as operating cash flow net of property and equipment additions). Accenture’s management believes that this information provides meaningful additional information regarding the company’s liquidity.
    •Percentage changes in revenues and bookings on a local currency basis. Financial results in local currency are calculated by restating current period activity into U.S. dollars using the comparable prior year period’s foreign currency exchange rates. This approach is used for all results where the functional currency is not the U.S. dollar. Accenture’s management believes that information regarding changes in its revenues and bookings that excludes the effect of fluctuations in foreign currency exchange rates facilitates meaningful comparison of its revenues.
    •Adjusted financial measures excluding the impact of business optimization costs in fiscal 2024. Accenture’s management believes that information regarding the effect of the business optimization costs facilitates an understanding as to the impact of this item and the company’s performance in comparison to the prior period.
    Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are included in the news release. While Accenture’s management believes that this non-GAAP financial information is useful in evaluating Accenture’s operations, this information should be considered as supplemental in nature and not as a substitute for the related financial information prepared in accordance with GAAP.

    Item 9.01 Financial Statements and Exhibits
    (d) Exhibits
    Exhibit No.Description
    99
    News Release of Accenture, dated June 20, 2025
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL



    Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

    Date: June 20, 2025ACCENTURE PLC
    By:/s/ Joel Unruch
    Name:  Joel Unruch
    Title:General Counsel & Corporate Secretary



    Get the next $ACN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACN

    DatePrice TargetRatingAnalyst
    3/17/2025$390.00Neutral → Outperform
    Robert W. Baird
    1/8/2025$425.00Peer Perform → Outperform
    Wolfe Research
    12/6/2024$370.00 → $420.00Neutral → Buy
    Goldman
    10/30/2024$375.00Outperform → Neutral
    Exane BNP Paribas
    9/30/2024$321.00 → $400.00Hold → Buy
    TD Cowen
    9/26/2024$329.00 → $395.00Neutral → Overweight
    Piper Sandler
    7/19/2024$400.00Neutral → Buy
    UBS
    6/26/2024$382.00 → $300.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings